Translational Development Acquisition Corp.
TDAC
$10.45
-$0.01-0.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 248.61% | 12,905.88% | 43,325.00% | -72.43% | 12,160.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 248.61% | 12,905.88% | 43,325.00% | -72.43% | 12,160.00% |
| Operating Income | -248.61% | -12,905.88% | -43,325.00% | 72.43% | -12,160.00% |
| Income Before Tax | 2,808.16% | 95,588.24% | 185,487.50% | 98.35% | -12,160.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2,808.16% | 95,588.24% | 185,487.50% | 98.35% | -12,160.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,808.16% | 95,588.24% | 185,487.50% | 98.35% | -12,160.00% |
| EBIT | -248.61% | -12,905.88% | -43,325.00% | 72.43% | -12,160.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 601.99% | 18,625.00% | 33,950.00% | 98.74% | -15,000.00% |
| Normalized Basic EPS | 598.95% | 15,533.33% | 42,400.00% | 98.80% | -9,400.00% |
| EPS Diluted | 601.99% | 18,625.00% | 33,950.00% | 98.74% | -15,000.00% |
| Normalized Diluted EPS | 598.95% | 15,533.33% | 42,400.00% | 98.80% | -9,400.00% |
| Average Basic Shares Outstanding | 440.93% | 440.93% | 440.93% | 33.82% | 0.00% |
| Average Diluted Shares Outstanding | 440.93% | 440.93% | 440.93% | 33.82% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |